Condition: Adult Solid Tumor · Sponsor: SQZ Biotechnologies
This is a Phase 1/2, first-in-human, open label, multicenter study to assess safety and tolerability, antitumor activity, and immunogenic and pharmacodynamic effects of SQZ-eAPC-HPV as monotherapy and in combination with pembrolizumab in patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors. The study includes patients with head and neck, cervical, anal, vulvar, or penile cancer.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Honor Health Research Institute | Scottsdale, Arizona, United States | — |
| City of Hope Medical Center | Duarte, California, United States | — |
| University of Colorado Anschutz Cancer Pavillion | Aurora, Colorado, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| Masonic Cancer Center, University of Minnesota | Minneapolis, Minnesota, United States | — |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | — |
| University of Cincinnati Medical Center | Cincinnati, Ohio, United States | — |
| Tennessee Oncology, PLLC | Nashville, Tennessee, United States | — |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05357898